[Not Available].
作者信息
Loucks Catrina M, Groeneweg Gabriella, Roy Carl, Lee David K, Rieder Michael J, Lebel Denis, Ito Shinya, Ross Colin J, Carleton Bruce C
机构信息
Boursière postdoctorale au Département de pédiatrie de l'Université de la Colombie-Britannique à Vancouver.
Gestionnaire de programmes au Département de pédiatrie de l'Université de la Colombie-Britannique.
出版信息
Can Fam Physician. 2020 Apr;66(4):247-249.
Abstract
摘要
相似文献
1
[Not Available].[无可用内容]。
Can Fam Physician. 2020 Apr;66(4):247-249.
本文引用的文献
1
An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.对接受蒽环类药物治疗的儿童癌症患者进行药物基因组学检测的初步卫生经济学评价。
Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26887. Epub 2017 Dec 22.
2
Pharmacogenomics: Precision Medicine and Drug Response.药物基因组学：精准医学与药物反应。
Mayo Clin Proc. 2017 Nov;92(11):1711-1722. doi: 10.1016/j.mayocp.2017.09.001. Epub 2017 Nov 1.
3
Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.关于基因检测以降低蒽环类药物所致心脏毒性发生率的建议。
Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30.
4
Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.使用药物遗传学标志物管理和预防顺铂所致听力损失的临床实践建议
Ther Drug Monit. 2016 Aug;38(4):423-31. doi: 10.1097/FTD.0000000000000298.
5
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.RARG基因中的一个编码变异赋予儿童癌症患者对蒽环类药物诱导的心脏毒性的易感性。
Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.
6
Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.临床实践指南：用于安全有效可待因治疗的CYP2D6基因分型
J Popul Ther Clin Pharmacol. 2013;20(3):e369-96. Epub 2013 Nov 6.
7
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.TPMT 和 ABCC3 基因变异体的复制与儿童顺铂诱导性听力损失高度相关。
Clin Pharmacol Ther. 2013 Aug;94(2):243-51. doi: 10.1038/clpt.2013.80. Epub 2013 Apr 10.
8
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.验证 SLC28A3 和 UGT1A6 中的变体是否可作为预测儿童蒽环类药物诱导性心脏毒性的遗传标志物。
Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. doi: 10.1002/pbc.24505. Epub 2013 Feb 25.
9
Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.利用母亲遗传标志物的新组合预测婴儿及其母亲的可待因毒性。
Clin Pharmacol Ther. 2012 Apr;91(4):692-9. doi: 10.1038/clpt.2011.280. Epub 2012 Mar 7.
10
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.临床药物遗传学实施联盟（CPIC）关于细胞色素 P450 2D6（CYP2D6）基因型背景下的可待因治疗指南。
Clin Pharmacol Ther. 2012 Feb;91(2):321-6. doi: 10.1038/clpt.2011.287. Epub 2011 Dec 28.
Zotero 插件